Alteogen enters into an Exclusive License Agreement to Develop and Commercialize Subcutaneous ENHERTU® Enabled by Alteogen's Hybrozyme™ Technology
DAEJEON, South Korea, Nov. 10, 2024 /PRNewswire/ -- Alteogen Inc. (KOSDAQ:196170) announced today that the company has entered into an exclusive license agreement with Daiichi Sankyo (TSE: 4568). Under the terms of the agreement, Daiichi Sankyo will acquire world-wide rights to use ALT-B4, Alteo...
International companies to host live webcasts at Deutsche Bank's June 9th and 10th Depositary Receipts Virtual Investor Conference
NEW YORK, June 6, 2016 /PRNewswire/ -- Deutsche Bank today announced the lineup for itsJune 9th and 10th Depositary Receipts Virtual Investor Conference ("dbVIC"), featuring live webcast presentations from international companies with American Depositary Receipt (ADR) programs in the US. Represe...
Daiichi Sankyo to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on Thursday, June 9th, 2016
TOKYO, June 6, 2016 /PRNewswire/ -- Daiichi Sankyo Co., Ltd. (JP: 4568.T, OTC Pink: DSNKY) based inTokyo, Japan and focused on pharmaceutical business, today announced that Senior Director, IR group, Mr.Junichi Onuma will present at the dbVIC - Deutsche Bank American Depositary Receipt (ADR) Virt...
